retatrutide new england journal of medicine (not yet approved in US but people using anyway) promises even potentially greater weight loss amongst the GLP1 drugs. https://www.nejm .org/doi/full/10.1056/NEJMoa2301972 Retatrutide, an investigational triple hormone

Update Surg

Clinical trial data from the STEP programme reported headaches in approximately 14% of participants receiving semaglutide compared to 10% in the placebo group

Frailty is a more extensive clinical syndrome involving a decline in physiological reserves in multiple systems, and sarcopenia is regarded as one of the key pathophysiological components constituting its phenotype [4]

All handling should be conducted by qualified professionals in compliance with institutional safety guidelines and applicable regulations

When patients over-restrict or over-dose, the resulting low insulin and high SHBG can reduce free testosterone, impair muscle preservation, and slow metabolism

If you experience significant side effects at any dose level, your provider should adjust the timeline rather than pushing you through discomfort